RESUMO
The purpose of this pilot study was to determine if there is a difference in metabolic cost when jumping on platforms of varying thickness, as well as whether a difference exists in metabolic cost between genders exists on the different platforms. Fourteen participants (seven males and seven females) completed three repetitive jumping trials on the DigiJump machine. Each trial was performed at a cadence of 120 jumps per minute and at a minimum height of 1/2â³ per jump. Trials were completed on platforms of 1/2â³, 3/8â³, and 1/4â³ thickness. Participants were instructed to jump as long as possible while maintaining the prescribed cadence or until fifteen minutes had elapsed. There were no differences observed in metabolic cost or exertion for all participants or between genders as indicated by oxygen consumption, respiratory exchange ratio, upper leg RPE, or lower leg RPE. There were also no differences for durations of exercise the participants were able to sustain on the machine. However, when comparing data between genders, a significant interaction was observed in total body RPE across the three platforms (p = .009) and in HR on the 1/2â³ platform (p = .018). Results from this study indicate that metabolic cost is similar during repetitive jumping regardless of platform rigidity or gender. However, post-trial comments from participants did show preferences towards specific platforms, though this was not apparent in exercise duration.
RESUMO
Astaxanthin (AX) is an antioxidant which may spare endogenous carbohydrates and improve fat oxidation rates, thus improving metabolic flexibility. To date, no studies have attempted to examine the impact of AX in an overweight cohort, whom often suffer from metabolic inflexibility. Nineteen subjects (mean ± SD: age: 27.5 ± 6.3 years; height: 169.7 ± 9.0 cm; body mass: 96.4 ± 17.9 kg; BF%: 37.9 ± 7.0%; BMI: 33.4 ± 5.6 kg/m2; VO2peak: 25.9 ± 6.7 ml·kg-1·min-1) were recruited and supplemented with either 12 mg of AX or placebo (PLA) for 4 weeks. Subjects completed a graded exercise test on a cycling ergometer to examine changes in substrate oxidation rates. A total of 5 stages, each lasting 5 min and resistance increased 15 W each stage, were completed to examine changes in levels of glucose and lactate, fat and carbohydrate (CHO) oxidation rates, heart rate, and rating of perceived exertion (RPE). Although there were no changes found in rates of fat oxidation, blood lactate or glucose, or RPE (all p > 0.05), a significant decrease was observed in CHO oxidation from pre to post supplementation in the AX group only. Further, the AX group demonstrated a 7% decrease in heart rate across the graded exercise test. These findings suggest that 4 weeks of AX supplementation may offer some cardiometabolic benefits to overweight individuals, and be a favorable supplement for these individuals beginning an exercise program.
